Preparation of Alendronate Liposomes for Enhanced Stability and Bioactivity: In Vitro and In Vivo Characterization
Journal Title: The AAPS Journal - Year 2008, Vol 10, Issue 4
Abstract
Liposomes containing bisphosphonates have been shown to deplete circulating monocytes and reduce experimental restenosis. However, acceptable shelf life was not achieved, and the disruption extent and rate of the vesicles in the circulation has not been examined. Designing an optimal liposomal formulation in general, and for an anti-inflammatory effect in particular, requires careful consideration of the factors that contribute to their in vitro stability and integrity in the blood after injection. An improved liposomal alendronate formulation was prepared by a modified thin lipid film hydration technique followed by extrusion, resulting in relatively smaller size vesicles, narrow size distribution, and low drug to lipid ratio in comparison to the reverse phase evaporation method. In order to rule out premature leakage of the drug, the integrity of the vesicles was examined by means of size-exclusion chromatography in vitro and in vivo, with subsequent analysis of size, drug (fractions of encapsulated and free) and lipid concentrations. Vesicles were found to be stable in serum, with 15 ± 3% leakage of the drug after 10 min in rabbit’s circulation, and intact liposomes were detected in the circulation 24 h following administration. It is concluded that the new formulation results in increased stability (2.5 years) as determined by the insignificant changes in vesicle size, drug leakage, lipid and drug stability, in vitro bioactivity (macrophages inhibition), as well as in vivo in depleting circulating monocytes and inhibition of restenosis in rabbits. Our in vitro stability results regarding dilution in serum paralleled in vivo data. Thus, in vitro assessment may provide a valuable tool in assessing in vivo integrity of liposomal formulations.
Authors and Affiliations
Hila Epstein, Dikla Gutman, Einat Cohen-Sela, Elran Haber, Omar Elmalak, Nickolay Koroukhov, Haim D. Danenberg, Gershon Golomb
Keywords
Related Articles
- EP ID EP681614
- DOI 10.1208/s12248-008-9060-5
- Views 80
- Downloads 0
Combined Inhaled Salbutamol and Mannitol Therapy for Mucus Hyper-secretion in Pulmonary Diseases
The online version of this article (doi:10.1208/s12248-014-9560-4) contains supplementary material, which is available to authorized users.
Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development
Model-based drug development (MBDD) has been recognized as a concept to improve the efficiency of drug development. The acceptance of MBDD from regulatory agencies, industry, and academia has been growing, yet today...
Gender-Dependent Pharmacokinetics of Veratramine in Rats: In Vivo and In Vitro Evidence
The online version of this article (doi:10.1208/s12248-016-9870-9) contains supplementary material, which is available to authorized users.
In vitro evaluation of chitosan-EDTA conjugate polyplexes as a nanoparticulate gene delivery system
It was the purpose of this study to evaluate the potential of different molecular-weight chitosan-EDTA conjugates as a carrier matrix for nanoparticulate gene delivery systems. Covalent binding of EDTA to more than one c...
Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology
Sodium–glucose co-transporter-2 (SGLT2) inhibitors are an emerging class of agents for use in the treatment of type 2 diabetes mellitus (T2DM). Inhibition of SGLT2 leads to improved glycemic control through incre...